EP0026848A1 - Dérivés de tétraline, leur préparation et médicaments contenant ces composés - Google Patents

Dérivés de tétraline, leur préparation et médicaments contenant ces composés Download PDF

Info

Publication number: EP0026848A1
Authority: EP; European Patent Office
Prior art keywords: carbon atoms; alkyl; group; acid addition; atoms
Prior art date: 1979-09-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP80105275A

Other languages

German (de)

English (en)

Other versions

EP0026848B1 (fr

Inventor

Max Peter Dr. Seiler

André Dr. Stoll

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-09-14

Filing date

1980-09-04

Publication date

1981-04-15

1980-09-04 Application filed by Sandoz AG filed Critical Sandoz AG

1980-09-04 Priority to AT80105275T priority Critical patent/ATE3204T1/de

1981-04-15 Publication of EP0026848A1 publication Critical patent/EP0026848A1/fr

1983-05-04 Application granted granted Critical

1983-05-04 Publication of EP0026848B1 publication Critical patent/EP0026848B1/fr

Status Expired legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 70
238000002360 preparation method Methods 0.000 title claims description 11
125000005329 tetralinyl group Chemical class C1(CCCC2=CC=CC=C12)* 0.000 title claims 2
239000003814 drug Substances 0.000 title description 2
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 77
125000000217 alkyl group Chemical group 0.000 claims abstract description 57
239000002253 acid Substances 0.000 claims abstract description 41
150000003839 salts Chemical class 0.000 claims abstract description 32
125000003545 alkoxy group Chemical group 0.000 claims abstract description 28
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
239000001257 hydrogen Substances 0.000 claims abstract description 21
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 17
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 13
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 9
229910052794 bromium Inorganic materials 0.000 claims abstract description 9
229910052801 chlorine Inorganic materials 0.000 claims abstract description 9
239000000460 chlorine Substances 0.000 claims abstract description 9
125000000524 functional group Chemical group 0.000 claims abstract description 9
125000003342 alkenyl group Chemical group 0.000 claims abstract description 8
229910052731 fluorine Inorganic materials 0.000 claims abstract description 8
239000011737 fluorine Substances 0.000 claims abstract description 8
229910052736 halogen Inorganic materials 0.000 claims abstract description 7
150000002367 halogens Chemical class 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
229910052717 sulfur Inorganic materials 0.000 claims abstract description 7
125000002947 alkylene group Chemical group 0.000 claims abstract description 6
125000003277 amino group Chemical group 0.000 claims abstract description 6
125000000304 alkynyl group Chemical group 0.000 claims abstract description 5
230000007062 hydrolysis Effects 0.000 claims abstract description 5
238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
230000004962 physiological condition Effects 0.000 claims abstract description 5
102000003946 Prolactin Human genes 0.000 claims abstract description 4
108010057464 Prolactin Proteins 0.000 claims abstract description 4
150000002148 esters Chemical class 0.000 claims abstract description 4
239000003112 inhibitor Substances 0.000 claims abstract description 4
229940097325 prolactin Drugs 0.000 claims abstract description 4
230000028327 secretion Effects 0.000 claims abstract description 4
208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 3
208000027089 Parkinsonian disease Diseases 0.000 claims abstract description 3
206010034010 Parkinsonism Diseases 0.000 claims abstract description 3
AUBNLLGXUCCYFZ-UHFFFAOYSA-N 6-amino-5,6,7,8-tetrahydronaphthalen-1-ol Chemical class C1=CC=C2CC(N)CCC2=C1O AUBNLLGXUCCYFZ-UHFFFAOYSA-N 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 17
125000006239 protecting group Chemical group 0.000 claims description 8
-1 Y-phenyl Chemical group 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
125000003884 phenylalkyl group Chemical group 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
YEFAHBGREYEVJM-UHFFFAOYSA-N 6-[3-methylsulfanylpropyl(propyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2CC(N(CCCSC)CCC)CCC2=C1O YEFAHBGREYEVJM-UHFFFAOYSA-N 0.000 claims description 2
FOHUHYKENVAVAP-UHFFFAOYSA-N 4-[(5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]butanenitrile Chemical compound C1=CC=C2CC(N(CCCC#N)CCC)CCC2=C1O FOHUHYKENVAVAP-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
101100295741 Gallus gallus COR4 gene Proteins 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
150000003254 radicals Chemical class 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000002585 base Substances 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 4
XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 4
JAAJQSRLGAYGKZ-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-ol Chemical class C1=CC=C2C(O)CCCC2=C1 JAAJQSRLGAYGKZ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
0 [*-]N(*)C(CC1)CC(C=CC2)=C1C2=* Chemical compound [*-]N(*)C(CC1)CC(C=CC2)=C1C2=* 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
JTACXJVXDKPXFJ-UHFFFAOYSA-N 3-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]propan-1-ol Chemical compound C1=CC=C(OC)C2=C1CC(N(CCCO)CCC)CC2 JTACXJVXDKPXFJ-UHFFFAOYSA-N 0.000 description 2
CQVWOJSAGPFDQL-UHFFFAOYSA-N 3-iodopropan-1-ol Chemical compound OCCCI CQVWOJSAGPFDQL-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000006193 alkinyl group Chemical group 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
ZCCDPMQLQFYDAB-UHFFFAOYSA-N n-(3-chloropropyl)-5-methoxy-n-propyl-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C(OC)C2=C1CC(N(CCCCl)CCC)CC2 ZCCDPMQLQFYDAB-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229940072033 potash Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
LDKSCZJUIURGMW-UHFFFAOYSA-N 1-isothiocyanato-3-methylsulfanylpropane Chemical group CSCCCN=C=S LDKSCZJUIURGMW-UHFFFAOYSA-N 0.000 description 1
HZELKDANOKOELS-UHFFFAOYSA-N 5-[(5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-propylamino]pentanenitrile Chemical compound C1=CC=C2CC(N(CCCCC#N)CCC)CCC2=C1O HZELKDANOKOELS-UHFFFAOYSA-N 0.000 description 1
NWWWGAKVHCSAEU-UHFFFAOYSA-N 5-bromopentanenitrile Chemical compound BrCCCCC#N NWWWGAKVHCSAEU-UHFFFAOYSA-N 0.000 description 1
VGHJBJVZSYFTIE-UHFFFAOYSA-N 5-methoxy-n-(3-methylsulfanylpropyl)-n-propyl-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C(OC)C2=C1CC(N(CCCSC)CCC)CC2 VGHJBJVZSYFTIE-UHFFFAOYSA-N 0.000 description 1
ICJPCRXVYMMSJY-UHFFFAOYSA-N 5-methoxy-n-propyl-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C(OC)C2=C1CC(NCCC)CC2 ICJPCRXVYMMSJY-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
125000006519 CCH3 Chemical group 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028293 Muscle contractions involuntary Diseases 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
VCYPZWCFSAHTQT-UHFFFAOYSA-N N-Desthienylethyl-rotigotine Chemical compound C1=CC=C2CC(NCCC)CCC2=C1O VCYPZWCFSAHTQT-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003874 central nervous system depressant Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 1
PYJJBHPYNLVWTG-UHFFFAOYSA-N methyl 4-[(5-acetyloxy-1,2,3,4-tetrahydronaphthalen-2-yl)-ethylamino]butanoate Chemical compound C1=CC=C(OC(C)=O)C2=C1CC(N(CCCC(=O)OC)CC)CC2 PYJJBHPYNLVWTG-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000005245 sintering Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton

Definitions

the invention relates to new tetraline derivatives, their preparation and pharmaceutical preparations which contain these compounds.
German Offenlegungsschrift No. 2 333 847 relates to a very broad class of tetrahydronaphthols, which act as plasticizers of water, as corrosion inhibitors in lubricants, as CNS depressants, as agents for the treatment of cardiac muscle fibrillation and cardiac arrhythmia in warm-blooded animals, and for lowering blood pressure and can be used as a disinfectant.
tetrahydronaphthols can carry a large number of substituents both in the aromatic and in the hydrogenated nucleus.
the hydroxyl group on the aromatic nucleus can be free or esterified, the hydrogenated six-membered ring can include carry a non-cyclic disubstituted amino group.
the present invention relates to new 2-amino-5-hydroxy-l, 2,3,4-tetrahydronaphthalenes which contain two alkyl groups on the N atom of the amino group, one of which is unsubstituted and the other carries at least one functional group, As well as their physiologically hydrolyzable esters and the acid addition salts of these compounds.
These compounds can also have substituents in the other positions, these are preferably in the aromatic ring.
a functional group is understood here to mean any reactive group common in organic chemistry, including halogen atoms and unsaturated C-C groups, but excluding aromatic rings. It should also be noted here that the functional group should be bound directly to the alkyl group and not via an aromatic ring.
R 3 represents an esterified OH group
the acid residue of this ester can be derived, for example, from a carboxylic acid R 1 COOH or a carbamic acid, which can be substituted on the N atom by hydrocarbon residues with 1 to 10 C atoms.
the 2-dialkylamino-l, 2,3,4-tetrahydronaphthalenes according to the invention, with free OH group in position 5, or their acid addition salts can e.g. be prepared by a) introducing an alkyl radical containing the functional group into 2-monoalkylamino-5-hydroxy-l, 2,3,4-tetrahydronaphthalenes or b) from 2-dialkylamino-5-hydroxy-1,2,3, 4-tetrahydronaphthalenes which carry at least one functional group on one of the alkyl radicals attached to the N atom and in which the 5-OH group. is protected by a protective group, this protective group is removed.
the compounds according to the invention esterified in position 5 can be prepared by reacting the tetraline derivatives not esterified in position 5 with an acid which can be split off under physiological conditions by hydrolysis or a reactive derivative of such an acid (process c).
the compounds according to the invention which are present as free bases can be converted into their acid addition salts in a manner known per se and vice versa.
the compounds according to the invention can e.g. form acid addition salts with inorganic acids such as hydrochloric acid or with organic acids such as malonic acid, fumaric acid, embonic acid, naphthalene-1,5-disulfonic acid, maleic acid etc.
Process a) can be carried out according to methods known per se for the preparation of tertiary amines.
the compounds of the formulas II and III are preferably heated in an inert solvent, such as dimethylformanide.
the condensation can be carried out in the presence of a base, e.g. tert. Amine or alkali metal barbonate or hydrogen carbonate.
the radical Z preferably represents chlorine, bromine, iodine, an alkylsulfonyloxy or arylsulfonyloxy group.
Process b) can be carried out according to methods known per se for the removal of a hydroxyl protective group.
R 8 preferably denotes a lower alkyl group, in particular the methyl group, an aralkyl group, in particular the benzyl group or an acyl group, in particular the acetyl group.
a Lewis acid in an inert organic solvent or alkali metal alkyl mercaptide in an inert polar organic solvent is preferably used.
the compound of formula II is preferably heated with an alcoholic hydrohalic acid.
Process c) can be carried out in a manner known for the acylation of phenols.
Acid halides or acid anhydrides for example, can be used as reactive derivatives of the carboxylic acids.
the reaction is preferably carried out in an acidic solvent such as trifluoroacetic acid or in the presence of a base e.g. Pyridine.
the compounds according to the invention can be isolated and purified in a manner known per se.
optically active compounds according to the invention can e.g. starting from optically active starting products (prepared by methods which are customary per se for the cleavage of racemates) (e.g. analogously to the preparation of the compound of Example 23).
the antipode or diastereomer separation can also be carried out with the compounds according to the invention.
the starting compounds e.g. the compounds of the formulas II and IV are either known or can be prepared in a manner known per se or analogously to the methods described in the examples.
the compounds of the formula IV can be prepared, for example, analogously to process a) or by converting a radical R in a compound of the formula IV into another radical R 3 , for example replacing a halogen atom with an S-alkyl group with an alkylthiol or oxidation of the S- Alkyl residue using hydrogen peroxide or sodium periodate to form the SO 2 alkyl or SO alkyl group.
the compounds according to the invention have interesting pharmacological properties and can therefore be used as pharmaceuticals e.g. be used for therapeutic purposes. In particular, they stimulate the dopamine receptors.
anesthetized dogs for example, they show a decrease in blood pressure and increased blood flow in the arteria mesenterica, which is characteristic of peripheral dopamine receptor stimulation, in doses from 0.1 to 10 mg / kg IV.
the compounds according to the invention can therefore be used for the treatment of cardiovascular diseases, in particular for the treatment of elevated blood pressure, and for the treatment of kidney failure and in the event of heart failure.
these compounds show a central dopamine receptor-stimulating effect.
This effect can be found in rats in which a unilaterial injury to the nigro-neostriatal dopamine web was produced by a 6-hydroxydopamine injection into the substantia nigra, with doses between about 0.3 to 5 mg / kg ip [method according to U. Ungerstedt, Acta physiol.scand. Suppl. 367, 69-93 (1973)].
a clear activation was recognizable by the fact that the rats rotated in the direction of the undenervated side.
the central dopaminergic properties of the new compounds were confirmed in the apomorphine stereotype test on the rat (see Belgian patent No. 831,488) after administration of 30 mg / kg ip.
the new substances can be used to treat Parkinsonism.
the compounds according to the invention have an inhibitory effect on prolactin secretion. This effect was observed in the male rat in doses from 0.1 to 10 mg / kg s.c. can be demonstrated by analyzing the serum prolactin concentration using the RIA method. The blood was drawn by decapitation. The compounds can therefore also be used as proliferation secretion inhibitors.
a daily dose between 2 and 1000 mg is indicated. This dose can also be administered in smaller doses 2-4 times a day or in sustained release.
a unit dose can contain between 0.5 and 500 mg of the active ingredient together with suitable pharmaceutically indifferent auxiliaries.
the compounds can also be used in the form of their pharmaceutically suitable acid addition salts. These show an activity similar to that of the free bases.
the invention also relates to pharmaceutical preparations which contain a compound according to the invention as a free base or as a pharmaceutically suitable acid addition salt.
These pharmaceutical preparations for example a solution or a tablet, can be prepared by known methods, using the customary auxiliaries and carriers.
Example 23 relates to the preferred compound.
the starting material can be produced as follows:

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP80105275A 1979-09-14 1980-09-04 Dérivés de tétraline, leur préparation et médicaments contenant ces composés Expired EP0026848B1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AT80105275T ATE3204T1 (de)	1979-09-14	1980-09-04	Tetralinderivate, ihre herstellung und heilmittel, welche diese verbindungen enthalten.

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CH8347/79		1979-09-14
CH834779		1979-09-14
CH554780		1980-07-18
CH5547/80		1980-07-18

Publications (2)

Publication Number	Publication Date
EP0026848A1 true EP0026848A1 (fr)	1981-04-15
EP0026848B1 EP0026848B1 (fr)	1983-05-04

Family

ID=25697939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP80105275A Expired EP0026848B1 (fr)	1979-09-14	1980-09-04	Dérivés de tétraline, leur préparation et médicaments contenant ces composés

Country Status (12)

Country	Link
US (1)	US4410519A (fr)
EP (1)	EP0026848B1 (fr)
AU (1)	AU542340B2 (fr)
CA (1)	CA1162934A (fr)
DE (1)	DE3062971D1 (fr)
DK (1)	DK390280A (fr)
ES (1)	ES495024A0 (fr)
FI (1)	FI802808A7 (fr)
IL (1)	IL61013A (fr)
NZ (1)	NZ194936A (fr)
PH (1)	PH16519A (fr)
PT (1)	PT71799B (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1981003491A1 (fr) *	1980-05-29	1981-12-10	Astra Laekemedel Ab	Derive de tetraline d'utilite therapeutique
WO1982004042A1 (fr) *	1981-05-11	1982-11-25	Folke Lars Erik Arvidsson	Derives iii de tetraline utiles therapeutiquement, procedes de preparation et preparations pharmaceutiques contenant ces composes
EP0168505A1 (fr) *	1984-05-22	1986-01-22	Whitby Research Incorporated	2-Aminotétralines substituées et procédé de synthèse
US4743618A (en) *	1983-01-03	1988-05-10	Nelson Research & Development Co.	Substituted 2-aminotetralins
EP0270947A3 (en) *	1986-12-10	1988-12-28	Bayer Ag	Substituted basic 2-aminotetralines
AU601961B2 (en) *	1985-12-20	1990-09-27	Whitby Research, Inc.	Method for reducing the intraocular pressure of mammals
EP0321968A3 (en) *	1987-12-23	1990-10-31	Simes, Societa Italiana Medicinali E Sintetici, S.P.A.	Compounds active on the cardiovascular system
US5153225A (en) *	1986-12-10	1992-10-06	Bayer Aktiengesellschaft	Substituted basic 2-aminotetralin in pharmaceuticals
WO1996030333A1 (fr) *	1995-03-27	1996-10-03	Smithkline Beecham Plc	Derives amines bicycliques et leur utilisation comme agents neuroleptiques
WO2005058296A1 (fr) *	2003-12-18	2005-06-30	Schwarz Pharma Ag	(s)-2-n-propylamino-5-hydroxytetraline utilisee comme agent therapeutique ayant un effet agoniste sur le recepteur d3
WO2009056791A1 (fr) *	2007-11-02	2009-05-07	Pliva Hrvatska D.O.O.	Procédés de préparation de composés pharmaceutiques
EP3409658A4 (fr) *	2016-01-29	2020-05-27	ONO Pharmaceutical Co., Ltd.	Dérivé de tétrahydronaphtalène

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL65501A (en) *	1981-05-08	1986-04-29	Astra Laekemedel Ab	1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
US5286747A (en) *	1981-05-08	1994-02-15	Per A. E. Carlsson	1-alkyl-2-aminotetralin derivatives
JPS5970653A (ja) *	1982-10-15	1984-04-21	Takeda Chem Ind Ltd	眼圧低下剤
US4500545A (en) *	1982-11-16	1985-02-19	Eli Lilly And Company	Hydroxyaminotetralincarboxamides
US4722933A (en) *	1985-12-20	1988-02-02	Nelson Research & Development Co.	Substituted 2-aminotetralins
EP0213080B1 (fr) *	1985-08-27	1992-05-20	Ciba-Geigy Ag	Dérivés hydrogénés de la pyridine
DE3623941A1 (de) *	1986-07-16	1988-01-28	Bayer Ag	Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel
US4943428A (en) *	1987-07-10	1990-07-24	Wright State University	Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
WO1991000727A1 (fr) *	1989-07-05	1991-01-24	Whitby Research, Inc.	2-aminotetralines substituees
US4968837A (en) *	1989-07-28	1990-11-06	Ethyl Corporation	Resolution of racemic mixtures
DK0471515T3 (da) *	1990-08-15	1997-07-21	Lilly Co Eli	Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
IT1251877B (it) *	1991-09-26	1995-05-26	Zambon Spa	Processo per la preparazione di 2-ammino-5,6 dimetossi-tetralina
US5382596A (en) *	1993-08-05	1995-01-17	Whitby Research, Inc.	Substituted 2-aminotetralins
HK1049156B (en) *	1999-11-23	2004-12-10	Ucb Manufacturing Ireland Limited	Improved process for preparing nitrogen-substituted aminotetralins
SE0001438D0 (sv)	2000-04-18	2000-04-18	Axon Chemicals Bv	New chemical compounds and their use in therapy
DE10041478A1 (de)	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
DE10334187A1 (de) *	2003-07-26	2005-03-03	Schwarz Pharma Ag	Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) *	2003-07-26	2007-07-05	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung von Depressionen
CN102010400B (zh)	2009-09-07	2015-02-04	药源药物化学（上海）有限公司	S-5-取代-n-2'-(噻吩-2-基-)乙基-1,2,3,4-四氢萘-2-胺或其手性酸盐和用于制备罗替戈汀
PL2723727T3 (pl) *	2011-06-27	2017-08-31	Shan Dong Luye Pharmaceutical Co., Ltd.	Sposób do przemysłowego wytwarzania podstawionego na azocie amino-5,6,7,8-tetrahydronaftolu

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2333847A1 (de) *	1972-07-03	1974-01-24	Squibb & Sons Inc	Tetrahydronaphthole, ihre salze und diese verbindungen enthaltende arzneimittel
US3991207A (en) *	1971-03-18	1976-11-09	Pfizer Inc.	Combination therapy for Parkinson's disease
DE2623417A1 (de) *	1975-05-30	1976-12-16	American Cyanamid Co	1,2,3,4-tetrahydro-4-oxo-(oder -oxy-)-1-naphthylharnstoffe und verfahren zu ihrer herstellung
DE2803582A1 (de) *	1978-01-27	1979-08-02	Sandoz Ag	Neue tetralinderivate, ihre herstellung und verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL298071A (fr) *	1963-06-04
US4057582A (en) *	1973-09-26	1977-11-08	Abbott Laboratories	Aminotetralins and use in inducing anesthesia
JPS5826332B2 (ja) *	1974-04-25	1983-06-02	武田薬品工業株式会社	テトラロ−ルカゴウブツノセイゾウホウ
DK254975A (da) *	1974-06-12	1975-12-13	Takeda Chemical Industries Ltd	Fremgangsmade til fremstilling af aminotetralolforbindelser
DE2752659A1 (de)	1976-12-07	1978-06-08	Sandoz Ag	Neue tetralinderivate, ihre herstellung und verwendung

1980
- 1980-09-04 DE DE8080105275T patent/DE3062971D1/de not_active Expired
- 1980-09-04 EP EP80105275A patent/EP0026848B1/fr not_active Expired
- 1980-09-08 FI FI802808A patent/FI802808A7/fi not_active Application Discontinuation
- 1980-09-10 IL IL61013A patent/IL61013A/xx unknown
- 1980-09-11 PH PH24565A patent/PH16519A/en unknown
- 1980-09-12 PT PT71799A patent/PT71799B/fr unknown
- 1980-09-12 CA CA000360185A patent/CA1162934A/fr not_active Expired
- 1980-09-12 NZ NZ194936A patent/NZ194936A/en unknown
- 1980-09-12 AU AU62382/80A patent/AU542340B2/en not_active Ceased
- 1980-09-12 ES ES495024A patent/ES495024A0/es active Granted
- 1980-09-12 DK DK390280A patent/DK390280A/da not_active Application Discontinuation
1981
- 1981-03-12 US US06/243,267 patent/US4410519A/en not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3991207A (en) *	1971-03-18	1976-11-09	Pfizer Inc.	Combination therapy for Parkinson's disease
DE2333847A1 (de) *	1972-07-03	1974-01-24	Squibb & Sons Inc	Tetrahydronaphthole, ihre salze und diese verbindungen enthaltende arzneimittel
DE2623417A1 (de) *	1975-05-30	1976-12-16	American Cyanamid Co	1,2,3,4-tetrahydro-4-oxo-(oder -oxy-)-1-naphthylharnstoffe und verfahren zu ihrer herstellung
DE2803582A1 (de) *	1978-01-27	1979-08-02	Sandoz Ag	Neue tetralinderivate, ihre herstellung und verwendung

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1981003491A1 (fr) *	1980-05-29	1981-12-10	Astra Laekemedel Ab	Derive de tetraline d'utilite therapeutique
WO1982004042A1 (fr) *	1981-05-11	1982-11-25	Folke Lars Erik Arvidsson	Derives iii de tetraline utiles therapeutiquement, procedes de preparation et preparations pharmaceutiques contenant ces composes
US4743618A (en) *	1983-01-03	1988-05-10	Nelson Research & Development Co.	Substituted 2-aminotetralins
EP0168505A1 (fr) *	1984-05-22	1986-01-22	Whitby Research Incorporated	2-Aminotétralines substituées et procédé de synthèse
AU601961B2 (en) *	1985-12-20	1990-09-27	Whitby Research, Inc.	Method for reducing the intraocular pressure of mammals
EP0270947A3 (en) *	1986-12-10	1988-12-28	Bayer Ag	Substituted basic 2-aminotetralines
US4880802A (en) *	1986-12-10	1989-11-14	Bayer Aktiengesellschaft	Substituted basic 2-aminotetralin useful as cardiotonic agents
US5153225A (en) *	1986-12-10	1992-10-06	Bayer Aktiengesellschaft	Substituted basic 2-aminotetralin in pharmaceuticals
US5026857A (en) *	1986-12-10	1991-06-25	Bayer Aktiengesellschaft	Substituted basic 2-aminotetralin in pharmaceuticals
US5151414A (en) *	1987-12-23	1992-09-29	Simes Societa Italiana Medicinali E Sintetici S.P.A.	Phenoxyethyl amine compounds active on the cardiovascular system
US5070106A (en) *	1987-12-23	1991-12-03	Simes Societa Italiana Medicinali E Sintetici S.P.A.	Compounds active on the cardiovascular system
EP0321968A3 (en) *	1987-12-23	1990-10-31	Simes, Societa Italiana Medicinali E Sintetici, S.P.A.	Compounds active on the cardiovascular system
WO1996030333A1 (fr) *	1995-03-27	1996-10-03	Smithkline Beecham Plc	Derives amines bicycliques et leur utilisation comme agents neuroleptiques
US6008219A (en) *	1995-03-27	1999-12-28	Smithkline Beech P.L.C.	Bicyclic amine derivatives and their use as anti-psychotic agents
WO2005058296A1 (fr) *	2003-12-18	2005-06-30	Schwarz Pharma Ag	(s)-2-n-propylamino-5-hydroxytetraline utilisee comme agent therapeutique ayant un effet agoniste sur le recepteur d3
US8609641B2 (en)	2003-12-18	2013-12-17	Ucb Pharma Gmbh	(S)-2-N-propylamino-5-hydroxytetralin as a D3-agonist
US9108900B2 (en)	2003-12-18	2015-08-18	Ucb Pharma Gmbh	Method of treating diseases that respond to therapy by dopamine or dopamine agonists
WO2009056791A1 (fr) *	2007-11-02	2009-05-07	Pliva Hrvatska D.O.O.	Procédés de préparation de composés pharmaceutiques
EP3409658A4 (fr) *	2016-01-29	2020-05-27	ONO Pharmaceutical Co., Ltd.	Dérivé de tétrahydronaphtalène
US10730830B2 (en)	2016-01-29	2020-08-04	Ono Pharmaceutical Co., Ltd.	Tetrahydronaphthalene derivative

Also Published As

Publication number	Publication date
DK390280A (da)	1981-03-15
ES8500204A1 (es)	1984-10-16
FI802808A7 (fi)	1981-01-01
EP0026848B1 (fr)	1983-05-04
IL61013A0 (en)	1980-11-30
PT71799B (fr)	1981-10-23
DE3062971D1 (en)	1983-06-09
PT71799A (fr)	1980-10-01
AU6238280A (en)	1981-03-19
US4410519A (en)	1983-10-18
ES495024A0 (es)	1984-10-16
AU542340B2 (en)	1985-02-21
PH16519A (en)	1983-11-10
IL61013A (en)	1984-08-31
NZ194936A (en)	1985-02-28
CA1162934A (fr)	1984-02-28

Legal Events

Date	Code	Title	Description
1981-02-16	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1981-04-15	17P	Request for examination filed	Effective date: 19800904
1981-04-15	AK	Designated contracting states	Designated state(s): AT BE CH DE FR GB IT LU NL SE
1983-02-14	ITF	It: translation for a ep patent filed
1983-03-04	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
1983-05-04	AK	Designated contracting states	Designated state(s): AT BE CH DE FR GB IT LI LU NL SE
1983-05-04	REF	Corresponds to:	Ref document number: 3204 Country of ref document: AT Date of ref document: 19830515 Kind code of ref document: T
1983-06-09	REF	Corresponds to:	Ref document number: 3062971 Country of ref document: DE Date of ref document: 19830609
1983-06-24	ET	Fr: translation filed
1983-08-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 19830824 Year of fee payment: 4
1983-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19830930
1984-03-20	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
1984-03-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
1984-05-23	26N	No opposition filed
1984-08-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 19840822 Year of fee payment: 5
1984-08-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 19840824 Year of fee payment: 5
1984-08-26	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 19840826 Year of fee payment: 5
1984-09-06	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 19840906 Year of fee payment: 5
1984-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Effective date: 19840930
1984-09-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 19840930 Year of fee payment: 5 Ref country code: BE Payment date: 19840930 Year of fee payment: 5
1984-12-19	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 19841219 Year of fee payment: 5
1985-09-04	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Effective date: 19850904
1985-09-05	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Effective date: 19850905
1985-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Effective date: 19850930 Ref country code: CH Effective date: 19850930
1986-03-31	BERE	Be: lapsed	Owner name: SANDOZ A.G. Effective date: 19850904
1986-04-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Effective date: 19860401
1986-04-30	GBPC	Gb: european patent ceased through non-payment of renewal fee
1986-05-16	NLV4	Nl: lapsed or anulled due to non-payment of the annual fee
1986-05-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19860530
1986-05-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
1986-06-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Effective date: 19860603
1986-07-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST
1988-11-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Effective date: 19881118
1995-01-31	EUG	Se: european patent has lapsed	Ref document number: 80105275.4 Effective date: 19860729

Publication	Publication Date	Title
EP0026848B1 (fr)	1983-05-04	Dérivés de tétraline, leur préparation et médicaments contenant ces composés
EP0153277B1 (fr)	1987-08-26	Dérivés de pleuromutiline, leur procédé de préparation et leur application
DE69023928T2 (de)	1996-04-18	DIAMINVERBINDUNGEN UND ARZNEIMITTEL GEGEN CEREBRALE STöRUNGEN DIE DIESE ENTHALTEN.
DE2824064A1 (de)	1978-12-14	Phthalazin-derivate, ihre herstellung und solche derivate enthaltende arzneimittel
DE69002474T2 (de)	1994-03-10	Carboxyalkyl-ether von 2-Amino-7-hydroxytetralin.
EP0105210B1 (fr)	1987-03-04	Dérivés de l'isoquinoléine, leur procédé de préparation compositions pharmaceutiques les contenant et leur utilisation
EP0000395B1 (fr)	1981-01-07	Dérivés de 2-pipérazinotétraline, leur préparation et leur utilisation comme médicament
EP0116360A1 (fr)	1984-08-22	Composé de 1-phényl-2-aminocarbonylindole, leur préparation et les médicaments les contenant
CH550768A (de)	1974-06-28	Verfahren zur herstellung neuer bis((4-hydroxy-3-hydroxymethylphenyl)aethanol)diamin-derivate.
DE2362754C2 (de)	1985-11-21	Cyclopropylalkylaminoreste enthaltende Oxazolinverbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0082461B1 (fr)	1987-03-04	Phénoxyalcanolamines et phénoxyalcanol-cycloalcoylamines substituées, procédé pour leur préparation, compositions pharmaceutiques contenant ces composés et intermédiaires
DE69611303T2 (de)	2001-07-05	Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
EP0065295A1 (fr)	1982-11-24	Dérivés de la tryptamine et de la thiényloxypropanolamine, procédé pour leur préparation, compositions pharmaceutiques les contenant et préparation de celles-ci
DE69711911T2 (de)	2002-11-21	Aryloxypropanolaminderivate, verfahren zu deren herstellung und deren verwendungen
DE2535599C2 (de)	1985-07-11	Substituierte Zimtsäureamide, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, welche diese Verbindungen enthalten
CH640507A5 (en)	1984-01-13	Process for preparing novel 1-aryloxy-2-hydroxy-3-aminopropanes
DE3642497A1 (de)	1988-06-23	Substituierte aminopropionsaeureamide, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung sowie die bei der herstellung anfallenden neuen zwischenprodukte
DE2753878A1 (de)	1978-06-15	Derivate des 1-(3,5-dichlorphenyl)- piperazins, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE2656678C2 (de)	1986-12-04	4-Amino-trans-decahydrochinolin-Derivate und Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2605824B2 (de)	1980-07-24	N-Acylaniline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE2609574B2 (de)	1977-10-27	1-(4-fluor-3-trifluormethylthio- phenyl)-piperazin, dessen salze, verfahren zu dessen herstellung und arzneimittel
EP0003298A2 (fr)	1979-08-08	Dérivés de 4-hydroxy-2-benzimidazoline-thione, leur procédé de préparation et compositions pharmaceutiques les contenant
EP0102929B1 (fr)	1987-07-01	Dérivés de propylamine, procédé de leur préparation, compositions pharmaceutiques contenant ces composés, ainsi que leur usage thérapeutique
CH643536A5 (de)	1984-06-15	Alkanolaminderivate.
DE2500692C3 (de)	1977-10-20	Derivate des 4-Amidoalkylen-4'oxy diphenyle